AAP News Vol. 13 No. 3 March 1997, p. 1
© 1997 American Academy of Pediatrics
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aringa, S. D.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

 Previous Article  |  Next Article 

Infanrix latest DTaP vaccine to win approval

Stefanie Dell' Aringa

Infanrix, SmithKline Beecham Biological's DTaP (diphtheria-tetanus-acellular pertussis) vaccine joins the growing number of combination vaccines in that field receiving Food and Drug Administration (FDA) licensure.

To be distributed by SmithKline Beecham Pharmaceuticals, Infanrix (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) is indicated for active immunization against diphtheria, tetanus and pertussis in infants and children 6 weeks to 7 years of age (prior to 7th birthday).

It is the only available DTaP vaccine included in the National Institutes of Health (NIH) Efficacy Trials, a company spokesman said.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?